Skip to main content
OpenTrials

Clinical trial condition

Unresectable Malignant Solid Neoplasm

Explore clinical trials studying Unresectable Malignant Solid Neoplasm. Study availability and eligibility vary by location and protocol.

37 public trials 14 recruiting studies
Refine in advanced search Browse all conditions

Unresectable Malignant Solid Neoplasm trial results

Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

NCT05564377

Conditions
Adnexal Diseases, Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, +36 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States
  • Alaska Women's Cancer Care Anchorage, Alaska, United States
  • CTCA at Western Regional Medical Center Goodyear, Arizona, United States
View all 483 locations
View Trial Details
Recruiting

Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

NCT05372614

Conditions
Digestive System Diseases, Digestive System Neoplasms, Endocrine Gland Neoplasms, +15 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care Irvine, California, United States
  • City of Hope at Irvine Lennar Irvine, California, United States
  • City of Hope Antelope Valley Lancaster, California, United States
View all 18 locations
View Trial Details
Recruiting

Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer

NCT05111561

Conditions
Advanced Malignant Solid Neoplasm, Breast Diseases, Breast Neoplasms, +13 more
Locations
  • Boston Medical Center Boston, Massachusetts, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • University of Texas Medical Branch Galveston, Texas, United States
  • UT MD Anderson Cancer Center Houston, Texas, United States
View Trial Details
Recruiting

Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

NCT05327010

Conditions
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Neoplasm Metastasis, +5 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • City of Hope at Irvine Lennar Irvine, California, United States
  • UC San Diego Moores Cancer Center La Jolla, California, United States
  • Keck Medicine of USC Koreatown Los Angeles, California, United States
View all 36 locations
View Trial Details
Recruiting

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

NCT07137416

Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Diseases, +24 more
Locations
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Washington University School of Medicine St Louis, Missouri, United States
View Trial Details
Recruiting

Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers

NCT05803382

Conditions
Colonic Diseases, Colorectal Neoplasms, Digestive System Diseases, +17 more
Locations
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care Irvine, California, United States
  • UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California, United States
  • UF Health Cancer Institute - Gainesville Gainesville, Florida, United States
  • Memorial Hospital East Shiloh, Illinois, United States
View all 22 locations
View Trial Details
Recruiting

Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes

NCT05687110

Conditions
Metastatic Malignant Solid Neoplasm, Neoplasm Metastasis, Neoplasms, +4 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care Irvine, California, United States
  • UC San Diego Moores Cancer Center La Jolla, California, United States
  • Los Angeles General Medical Center Los Angeles, California, United States
View all 23 locations
View Trial Details
Recruiting

Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors

NCT05687136

Conditions
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Neoplasm Metastasis, +5 more
Locations
  • National Cancer Institute Developmental Therapeutics Clinic Bethesda, Maryland, United States
  • National Institutes of Health Clinical Center Bethesda, Maryland, United States
  • Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
View Trial Details

Related conditions